Patents by Inventor Barry A Springer

Barry A Springer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chemically modified quinoline and quinolone derivatives useful as CB-1 inverse agonists
    Patent number: 9815790
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the CB1 receptor. Such compounds are represented by Formula (I) wherein R1, R2, R3, L1, n, v, r, w, and g are defined herein. and further represented by Formula (II) wherein the group “X?Y”, ring A, R10, R11, R30, W, and t are defined herein.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: November 14, 2017
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark J. Macielag, Yue-Mei Zhang, Michael N. Greco, Barry A. Springer, William V. Murray
  • CHEMICALLY MODIFIED QUINOLINE AND QUINOLONE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS
    Publication number: 20170057922
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the CB1 receptor. Such compounds are represented by Formula (I) wherein R1, R2, R3, L1, n, v, r, w, and g are defined herein. and further represented by Formula (II) wherein the group “X?Y”, ring A, R10, R11, R30, W, and t are defined herein.
    Type: Application
    Filed: August 17, 2016
    Publication date: March 2, 2017
    Applicant: Janssen Pharmaceutica NV
    Inventors: Mark J. Macielag, Yue-Mei Zhang, Michael N. Greco, Barry A. Springer, William V. Murray
  • METHODS OF INHIBITING PRO MATRIX METALLOPROTEINASE ACTIVATION
    Publication number: 20120302573
    Abstract: This invention relates to methods for preventing, treating or ameliorating an MMP9 and/or MMP13 mediated syndrome, disorder or disease comprising administering to a subject in need thereof an effective amount of a compound listed in the examples section of this specification, or a form, composition or medicament thereof. Disorders treated and/or prevented include rheumatoid arthritis.
    Type: Application
    Filed: May 24, 2012
    Publication date: November 29, 2012
    Inventors: Paul Francis JACKSON, Carl Manthey, Kenneth Rhodes, Robert Scannevin, Kristi Anne Leonard, Joseph Kent Barbay, Matthew Todd, Barry A. Springer
  • Methods of using analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamate 89, asparate 101 or leucine 137
    Patent number: 7138374
    Abstract: The present invention relates to novel muteins of human basic fibroblast growth factor with superagonist properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for stimulating cell division, treating a wound, treating ischemia, treating heart disease, treating neural injury, treating peripheral vascular disease, treating a gastric ulcer and treating a duodenal ulcer.
    Type: Grant
    Filed: February 23, 2004
    Date of Patent: November 21, 2006
    Assignee: 3-Dimensional Pharmaceuticals, Inc.
    Inventors: Barry A. Springer, Michael W. Pantoliano, Celia M. Sharp
  • Analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamate 89, Aspartate 101 or Leucine 137
    Patent number: 6767722
    Abstract: The present invention relates to muteins of human basic fibroblast growth factor with superagonist properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed is a method for stimulating cell division.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: July 27, 2004
    Assignee: 3-Dimensional Pharmaceuticals, Inc.
    Inventors: Barry A. Springer, Michael W. Pantoliano, Celia M. Sharp
  • Methods of using analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamate 89, aspartate 101 or leucine 137
    Patent number: 6737404
    Abstract: The present invention relates to novel muteins of human basic fibroblast growth factor with superagonist properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for stimulating cell division, treating a wound, treating ischemia, treating heart disease, treating neural injury, treating peripheral vascular disease, treating a gastric ulcer and treating a duodenal ulcer.
    Type: Grant
    Filed: April 5, 2001
    Date of Patent: May 18, 2004
    Assignee: 3-Dimensional Pharmaceuticals, Inc.
    Inventors: Barry A. Springer, Michael W. Pantoliano, Celia M. Sharp
  • Microplate thermal shift assay for ligand development using 5- (4"-dimethylaminophenyl) -2- (4' -phenyl) oxazole derivative fluorescent dyes
    Publication number: 20030175813
    Abstract: The present invention provides a method for ranking the affinity of each of a multiplicity of different molecules for a target molecule which is capable of unfolding due to a thermal change.
    Type: Application
    Filed: February 14, 2003
    Publication date: September 18, 2003
    Applicant: 3-Dimensional Pharmaceuticals, Inc.
    Inventors: Michael W. Pantoliano, Eugenio C. Petrella, F. Raymond Salemme, Barry A. Springer
  • Microplate thermal shift assay for ligand development using 5-(4?dimethylaminophenyl)-2-(4?-phenyl)oxazole derivative fluorescent dyes
    Patent number: 6569631
    Abstract: The present invention provides a method for ranking the affinity of each of a multiplicity of different molecules for a target molecule which is capable of unfolding due to a thermal change.
    Type: Grant
    Filed: November 12, 1999
    Date of Patent: May 27, 2003
    Assignee: 3-Dimensional Pharmaceuticals, Inc.
    Inventors: Michael W. Pantoliano, Eugenio C. Petrella, F. Raymond Salemme, Barry A. Springer
  • Microplate thermal shift assay for ligand development and multi-variable protein chemistry optimization
    Patent number: 6291191
    Abstract: The present invention is a method for ranking the affinity of each of a multiplicity of different molecules for a target molecule which is capable of denaturing due to a thermal change.
    Type: Grant
    Filed: December 2, 1999
    Date of Patent: September 18, 2001
    Assignee: 3-Dimensional Pharmaceuticals, Inc.
    Inventors: Michael W. Pantoliano, Eugenio C. Petrella, Alexander W. Rhind, Francis R. Salemme, Barry A. Springer
  • Method for identifying conditions that facilitate recombinant protein folding
    Patent number: 6291192
    Abstract: The present invention is a method for ranking the affinity of each of a multiplicity of different molecules for a target molecule which is capable of denaturing due to a thermal change.
    Type: Grant
    Filed: January 5, 2000
    Date of Patent: September 18, 2001
    Assignee: 3-Dimensional Pharmaceuticals Inc.
    Inventors: Michael W. Pantoliano, Eugenio C. Petrella, Francis R. Salemme, Barry A. Springer
  • Analogs of human basic fibroblast growth factor
    Publication number: 20010020004
    Abstract: The present invention relates to novel muteins of human basic fibroblast growth factor with superagonist properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for stimulating cell division, treating a wound, treating ischemia, treating heart disease, treating neural injury, treating peripheral vascular disease, treating a gastric ulcer and treating a duodenal ulcer.
    Type: Application
    Filed: April 5, 2001
    Publication date: September 6, 2001
    Applicant: 3-Dimensional Pharmaceuticals, Inc.
    Inventors: Barry A. Springer, Michael W. Pantoliano, Celia M. Sharp
  • Analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamute 89, aspartate 101 or leucine 137
    Patent number: 6274712
    Abstract: The present invention relates to muteins of human basic fibroblast growth factor with superagonist properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of the nucleic acid sequences and the production of the muteins.
    Type: Grant
    Filed: December 23, 1998
    Date of Patent: August 14, 2001
    Assignee: 3-Dimensional Pharmaceuticals, Inc.
    Inventors: Barry A. Springer, Michael W. Pantoliano, Celia M. Sharp
  • Method for determining conditions that facilitate protein crystallization
    Patent number: 6268158
    Abstract: The present invention is a method for ranking the affinity of each of a multiplicity of different molecules for a target molecule which is capable of denaturing due to a thermal change.
    Type: Grant
    Filed: December 10, 1999
    Date of Patent: July 31, 2001
    Assignee: 3-Dimensional Pharmaceuticals, Inc.
    Inventors: Michael W. Pantoliano, Eugenio C. Petrella, Francis R. Salemme, Barry A. Springer
  • Method for determining conditions that stabilize proteins
    Patent number: 6232085
    Abstract: The present invention is a method for ranking the affinity of each of a multiplicity of different molecules for a target molecule which is capable of denaturing due to a thermal change.
    Type: Grant
    Filed: December 10, 1999
    Date of Patent: May 15, 2001
    Assignee: 3-Dimensional Pharmaceuticals, Inc.
    Inventors: Michael W Pantoliano, Eugenio C Petrella, Francis R Salemme, Barry A Springer